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The immune suppressive and anti-inflammatory capabilities of bone marrow-derived mesenchymal stromal
cells (MSCs) represent an innovative new tool in regenerative medicine and immune regulation. The potent
immune suppressive ability of MSC over T cells, dendritic cells, and natural killer cells has been extensively
characterized, however, the effect of MSC on B cell function has not yet been clarified. In this study, the direct
effect of MSC on peripheral blood B cell function is defined and the mechanism utilized by MSC in enhancing
B cell survival in vitro identified. Human MSC supported the activation, proliferation, and survival of purified
CD19+ B cells through a cell contact-dependent mechanism. These effects were not mediated through B cell
activating factor or notch signaling. However, cell contact between MSC and B cells resulted in increased
production of vascular endothelial growth factor (VEGF) by MSC facilitating AKT phosphorylation within the
B cell and inhibiting caspase 3-mediated apoptosis. Blocking studies demonstrated that this cell contact-
dependent effect was not dependent on signaling through CXCR4-CXCL12 or through the epidermal growth
factor receptor (EGFR). These results suggest that direct cell contact between MSC and B cells supports B cell
viability and function, suggesting that MSC may not represent a suitable therapy for B cell-mediated disease.
Introduction
Mesenchymal Stem or Stromal Cells (MSCs) are aheterogeneous cell population first described in the
bone marrow but subsequently identified in almost every
tissue [1,2]. MSC form plastic-adherent colonies in vitro and
are capable of osteocyte, adipocyte, or chondrocyte differ-
entiation [3]. However, the conceptual focus of usingMSC in
regenerative medicine has shifted with an appreciation of the
wide range of MSC secreted trophic factors capable of pro-
moting tissue repair and potent immunemodulation [1]. The
ability of allogeneic MSC to suppress T cell proliferation
[4,5], dendritic cell (DC) [6–8] and natural killer (NK) cell
function [9,10] has now been extensively characterized. In
contrast to the detailed understanding of how MSC modulate
T, DC, and NK cell function, the effect of MSC on B cells is
poorly characterized and published studies present conflict-
ing results [11–18].
B cells develop from hematopoietic progenitor cells in the
fetal liver and postnatal bone marrow [19] before migrating to
the lymph nodes where the recognition of foreign antigen
signals their development. B cell maturation is a complex and
tightly controlled process [20], however, dysregulation in B cell
development can result in the production of self-recognizing
antibodies and subsequent autoimmune diseases.
The effect of human MSC on the B cell immune response
has been analyzed over the last number of years; however, the
effect of MSC on B cell biology in vitro is poorly charac-
terized and studies into MSC modulation of B cell biology
have presented conflicting results [13–18]. While the majority
of the published data suggest that MSC inhibit B cell function
[13,14,18], other publications have demonstrated a supportive
role for MSC in B cell expansion and differentiation
[15,16,21]. The mechanism by which MSC either support or
inhibit B cell function has yet to be identified; however, a
requirement for cell contact has been suggested [15,16,21].
Recent studies have demonstrated that MSC are capable
of either inhibiting or supporting B cell proliferation and
antibody production depending on the presence of T cells in
the coculture [21,22]. MSC inhibit the proliferation and
differentiation of stimulated B cells in whole peripheral
blood lymphocyte populations or in coculture with CD4+ T
cells, but support proliferation and antibody production
when cultured with pure B cell populations [21,22].
The immunemodulatory ability of MSC offers consider-
able possibilities for regenerative medicine and a potential
treatment for a variety of immune disorders. However, to
further the development of MSC toward clinical application it
is essential to clarify exactly how MSC interact with all cells
of the immune response. In this study, the effect of MSC on B
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cell function is defined and the mechanism utilized by MSC
in enhancing B cell survival in vitro identified.
Materials and Methods
Human MSC isolation and culture
The research was approved by the Institutional Review
Boards and Biological Ethics Committee of the National
University of Ireland, Maynooth. All human participants were
provided written informed consent. Human bone marrow
MSC were generated as previously described [23] in collab-
oration with REMEDI at the National University of Ireland
Galway. Human MSC conformed to criteria established by
ISCT and were capable of differentiation to adipocyte,
chondrocytem, and osteocyte lineages. All experiments were
conducted using MSC between passages 4–7 (*10–21 pop-
ulation doublings). Human MSC were cultured in Dulbecco’s
modified Eagle’s medium (Sigma-Aldrich) supplemented
with 10% fetal bovine serum (FBS) (BioSera), 200U/mL
penicillin, and 200mg/mL streptomycin (Sigma-Aldrich).
Isolation of PBMC and separation of CD19+ B cells
Peripheral blood mononuclear cells (PBMC) were iso-
lated from buffy packs, generously provided by the Irish
Blood Transfusion Service. PBMC were isolated by Ficoll-
density centrifugation and peripheral B cells were isolated
using CD19+ positive selection MACS beads (Miltenyi
Biotec). The purity of peripheral CD19+ B cell isolations
was verified using flow cytometry for human CD20.
Cell cultures
For each culture condition 9 · 105 B cells were cultured in
tissue culture grade six-well plates preseeded with or with-
out 1.8 · 105 MSC in Iscove’s modified Dulbecco’s medium
(Sigma-Aldrich) supplemented with 10% heat-inactivated FBS
(BioSera), 1% penicillin-streptomycin (Sigma-Aldrich), 1% l-
Glutamine (Sigma-Aldrich), and 0.01% 2-bmercapthoethanol
(Life Sciences). For studies requiring B cell activation and
proliferation, B cells were activated using a cytokine cocktail
of 25ng/mL recombinant interleukin-10 (IL-10) (Peprotech),
100U/mL recombinant IL-2 (Peprotech), 100ng/mL recom-
binant IL-21 (Peprotech), insulin-transferrin-selenium (1:
1,000) (Gibco), 250 ng/mL recombinant CD40L (Peprotech),
and 2.5mg/mL CpG-ODN (Invivogen).
For experiments investigating B cell activation, purified
CD19+ B cells were stained with CD19 and CD69. For
experiments examining the effect of MSC on B cell pro-
liferation, purified CD19+ B cells were stained with 10 mM
carboxyfluorescein succinimidyl ester (CFSE) (Invitrogen).
After 5 days, B cell proliferation was determined using an
Accuri C6 flow cytometer (BD biosciences). For experi-
ments investigating B cell viability, dual staining with
FITC-conjugated Annexin V and Propidium Iodide (PI) was
performed using a commercially available kit (eBioscience)
to visualize apoptotic B cell populations on an Accuri C6
flow cytometer.
Antibody and cytokine production
Quantitative analysis of IgG and IgM production by CD19+
B cells was performed by ELISA (eBioscience) according to
manufacturer’s instructions. Vascular endothelial growth factor
(VEGF) production by MSC was analyzed by ELISA (Pepro-
tech) according to manufacturer’s instructions. VEGF produc-
tion was also examined by intracellular cytokine staining.
Following B cell and MSC coculture in the presence of the
activation cocktail, 1· brefeldin A (eBioscience) was added
for the last 4 h of the 48h culture. Cells were surface stained
with CD45, CD19, and CD73. Cells were then incubated in
fixation/permeabilization buffer according to manufacturer’s
instructions (eBioscience), followed by incubation in per-
meabilization buffer (eBioscience), blocking with 2% rat
serum (Sigma-Aldrich) and incubation with mouse anti-
human VEGF or matched isotype control (R&D Systems).
MSCwere gated onCD73+CD45- populations andB cells were
gated on CD45+CD19+ populations and expression of intra-
cellular VEGF analyzed using an Accuri C6 flow cytometer.
Cell contact-dependent assays
Assays investigating cell contact dependence were per-
formed using transmembrane inserts with 0.4 mm pores
(Greneir Bio-One). 9· 105 CD19+ B cells were seeded in
the upper chamber of six-transwell tissue culture plates.
About1.8 · 105 MSC were seeded in the lower chamber.
Cells were cultured as previously described and cell pro-
liferation and viability were analyzed using an Acurri C6
flow cytometer.
In vitro neutralization experiments
In vitro neutralization assays were carried out to deter-
mine whether Notch, BAFF, CXCR4-CXCL12, or epider-
mal growth factor receptor (EGFR) signaling were required
for MSC support of peripheral B cell proliferation and
survival. Inhibition of Notch signalling was established by
adding increasing concentrations (1–10 mM) of GSI XII
(Merck Millipore) to B cell:MSC cocultures. BAFF inhi-
bition was achieved using specific neutralizing antibody
(R&D Systems). CXCR4 signaling was blocked via the
addition of AMD3100 (Sigma-Aldrich) to B cell:MSC co-
culture experiments and EGFR stimulation was inhibited
using specific blocking antibodies (Tocris Bioscience). In-
hibition of VEGF signaling on peripheral B cells was
achieved by adding vascular endothelial growth factor re-
ceptor (VEGFR) (R&D) to B cell:MSC cocultures.
Western blot analysis
Western blot analysis was performed to analyze the ex-
pression BAFF by human MSC and the expression of in-
tracellular proteins by B cells following MSC coculture. B
cells were carefully removed from coculture by gentle as-
piration. Samples were centrifuged at 300g for 5min and
pellet resuspended in lysis buffer [50mM HEPS, 1mM
EDTA, 10% Glycerol, 0.05% CHAPS, 0.5% Triton X,
250mM NaCl, 1mM NaVO3, 1mM PMSF, and complete
protease inhibitor ‘‘cocktail’’ (Roche)] and incubated on ice
for 30min. Samples were centrifuged at 300 g for 5min at
4C and cell lysate was removed and stored at -20C until
required for use. Cell lysates were probed with anti-human
antibodies for BAFF (R&D Systems), phosphorylated AKT,
cleaved Caspase 3 (both Cell Signalling) with b-actin (Cell
Signalling) used as a control.
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Real-time PCR analysis
Real-time polymerase chain reaction (PCR) analysis was
performed to determine the mRNA expression levels of BAFF
in resting and stimulated MSC. TriReagent (Life Technolo-
gies) was used to isolate total RNA and samples were reverse
transcribed to cDNA using Tetro cDNA synthesis kit (Bio-
Line). Real-time PCR analysis was performed using SYBR
Green reagent (Sigma-Aldrich) and specific primers were
utilized to determine gene expression. The following PCR
predesigned primers (Sigma-Aldrich) were used to determine
BAFF expression: 5¢–3¢ AATTTAACAGACAGCCACAG
and 3¢–5¢ TGTCCTTCCTCCAAGATAAG. GAPDH expres-
sion: 5¢–3¢ ACAGTTGCCATGTAGACC and 3¢–5¢ TTTTT
GGTTGAGCACAGG was used as housekeeping gene.
Results
MSCs support the activation and significantly
enhance proliferation of CD19+ peripheral B cells
B cell activation following antigen recognition or appro-
priate CD4+ T cell signaling, triggers B cell clonal expansion,
isotype switching, and the development of antibody-producing
plasma cells and memory B cells [24]; however, previous
studies investigating the ability of MSC to modulate B cell
activation, proliferation, and antibody production have pro-
vided contradictory results [13–18,22]. This study was de-
signed to determine how MSC directly affect purified CD19+
peripheral B cell biology.
To determine the effect of MSC on the activation of B cells,
CD19+ peripheral B cells were cocultured with MSC (5:1 B
cell:MSC) for 48 h in the presence of human IL-10, IL-2, IL-
21, and activating molecules CD40L and CpG. The upregu-
lation of the early lymphocyte activation marker CD69 was
analyzed by flow cytometry. Stimulation of CD19+ B cells
significantly increased CD69 expression on B cells as ex-
pected. However, expression of CD69 was further enhanced
when CD19+ B cells were activated in the presence of MSC
(Fig. 1A). Notably, CD69 expression was not enhanced on
CD19+ B cells cultured in the presence of MSC in the absence
of B cell stimulation cocktail suggesting that MSC supported
but did not induce the activation of B cells (Fig. 1A).
The proliferation of activated CD19+ B cells was deter-
mined using CFSE analysis. Following activation in the
presence of MSC, there were significantly less nonproliferat-
ing (0 divisions) B cells and significantly more B cells, which
had gone through at least five divisions compared to B cells
activated without MSC (Fig. 1B). The dependence of cell
contact in MSC support of B cell proliferation was examined
using a transwell coculture system, separating B cells from the
MSC. Inhibition of cell contact completely abrogated MSC
support of B cell proliferation demonstrating the requirement
for a cell contact-dependant mechanism (Fig. 1C). IgG and
IgM production by B cells during MSC cocultures was ana-
lyzed after 72 h by ELISA. In contrast to results observed for B
cell proliferation and activation, total levels of IgG and IgM
were not affected by MSC coculture (Fig. 1D, E).
MSCs protect CD19+ peripheral B cells from apoptosis
through a contact-dependent mechanism
A role for MSC in maintaining the hematopoietic stem
cell niche has previously been identified [25]. MSC are
capable of supporting the survival of immune cells through
contact-dependent and soluble mechanisms and the ability
for MSC to support B cell viability in vitro may explain the
enhanced activation and proliferation of B cells after co-
culture with MSC (Fig. 1A, B).
To investigate the effect of MSC on the survival of
CD19+ peripheral B cells, B cells were isolated from PBMC
and cultured in the presence or absence of MSC (5:1 B
cell:MSC ratio) for 72 h. In the absence of MSC, the via-
bility of B cells was very low with*20% of cells negative
for apoptosis markers Annexin V/PI, as analyzed by flow
cytometry (Fig. 2A). However, B cells cultured in the
presence of MSC demonstrated significantly elevated via-
bility illustrated by the significant increase in the percentage
and number of Annexin V- PI- B cells (Fig. 2). Preventing
cell contact abrogated the protection of CD19+ B cell sur-
vival by MSC and the percentage and cell number of An-
nexin V- PI- B cells was restored to a similar level of B
cells cultured alone (Fig. 2).
MSC support of B cell survival is not dependent
upon BAFF or Notch signaling
In addition to the data presented in the previous section
other studies examining the effect of MSC on B cell biology
have also demonstrated the requirement of a cell contact
signal [16], however, this contact signal has not yet been
elucidated. B cell activating factor (BAFF) is a member of the
tumor necrosis factor (TNF) superfamily of receptors, which
functions both as a surface bound protein and soluble factor,
and is known to bind TNSFR13 on B cells and support
proliferation, activation, and survival [26].
The expression of BAFF by human adipose-derived MSC
has previously been shown [27]. Therefore, to determine the
importance of BAFF in mediating the support of B cell sur-
vival and proliferation by MSC, the ability of bone marrow-
derived MSC to produce BAFF was probed by real-time PCR
and verified by immunoblotting. MSC constitutively express
low levels of BAFF but stimulation of MSC with proin-
flammatory cytokines interferon gamma (IFN-g) or TNF-a
clearly indicate that BAFF expression is inducible on MSC
(Fig. 3A, B). To determine whether BAFF-BAFFR was the
signal used by MSC to promote B cell proliferation, BAFF
signaling was neutralized during B cell:MSC coculture (Fig.
3C). However, inhibition of BAFF signaling did not prevent
MSC from enhancing B cell proliferation (Fig. 3C).
Another important cell contact-dependent signal known
to play a key role in B cell survival is notch. Notch signaling
is essential for interactions between immune cells and their
environment [28] and is critical during peripheral B cell
development [29]. Notch signaling is known to upregulate
the antiapoptotic Bcl-2 pathway and support B cell survival
[30]. Over the last number of years, the importance of the
notch signalling pathway in immune modulation by MSC
has been clearly identified. The roles for notch signaling in
MSC modulation of DC maturation and antigen presentation
[31] and in the induction of regulatory T cells [32,33] have
now been established. Therefore, it was hypothesized that
notch signaling between MSC and CD19+ B cells increased
peripheral B cell viability.
Notch signaling was inhibited during B cell:MSC cocul-
tures using the specific notch signaling inhibitor GSI XII.
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The presence of GSI XII during MSC:B cell cocultures had
no effect on the viability of peripheral B cells, suggesting that
the ability of MSC to support the survival of CD19+ B cells
was independent of the notch signaling pathway (Supple-
mentary Fig. S1A, B; Supplementary Data are available
online at www.liebertpub.com/scd).
Cell contact-dependent production of VEGF
by MSC promotes B cell survival
VEGF was originally identified as a proangiogenic factor
[34] and its production by a number of stromal cells including
MSC has since been reported [35]; however, one of the most
FIG. 1. Mesenchymal stem or stromal cell (MSC) supported the activation and enhanced the expansion of CD19+
peripheral B cells. CD19+ B cells isolated from peripheral blood mononuclear cell (PBMC) using positive selection CD19+
MACS beads were cultured with or without MSC and analyzed for the expression of early lymphocyte activation marker
CD69 after 48 h. The expression of CD69 was also analyzed on CD19+ B cells, which were activated with CD40L and CpG
in the presence or absence of MSC (A). CD19+ peripheral B cells were stained with carboxyfluorescein succinimidyl ester
(CFSE) and activated with CD40L and CpG in the presence of interleukin-10 (IL-10), IL-2, and IL-21, with or without MSC
for 120 h. Proliferation of CD19+ B cells was then analyzed by flow cytometry (B). Transwell membrane inserts (0.4mm
pore size) were used to prevent cell contact between MSC and CFSE-labeled CD19+ B cells during coculture before the
proliferation of B cells was analyzed by flow cytometry (C). IgG and IgM production was analyzed from supernatant
isolated after 72 h coculture by ELISA (D, E). n = 5 PBMC donors with 2 MSC donors for A and 8 PBMC donors with 2
MSC donors for (B, C). n = 4 PBMC donors with 2 MSC donors for (D, E). Student’s t-test was used to determine
significance where * < 0.05, ***< 0.001.
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FIG. 2. MSC significantly increased B cell survival in a contact-dependent manner. CD19+ peripheral B cells were
cultured with or without transwell inserts in the presence or absence of MSC for 72 h. B cell viability was determined by
analyzing the percentage (A) and total cell number (B) of Annexin V- PI- B cells after coculture with MSC. Viable B cells
were distinguished from MSC by gating on CD45+ cells before Annexin V and Propidium Iodide (PI) analysis. Total cell
numbers were generated using counting beads. n = 3 PBMC donors with 3 MSC donors. Statistical significance was
determined using paired Student’s t-test where *< 0.05, ** < 0.005.
FIG. 3. BAFF signaling
was not required for MSC
support of B cell prolifera-
tion or survival. The expres-
sion of total BAFF mRNA
(A) and both membrane
bound and soluble BAFF
protein (B) expression by
MSC stimulated with 50 ng/
mL interferon gamma (IFN-
g) or 20 ng/mL tumor necro-
sis factor alpha (TNF-a) for
8, 12, or 24 h was determined
by western blot and real-time
polymerase chain reaction,
respectively. CD19+ periph-
eral B cells were isolated,
labeled with CFSE, and cul-
tured with or without MSC
and in the presence or ab-
sence of 50mg/mL BAFF
inhibitor for 120 h. B cell
proliferation was measured
by flow cytometry (C). n = 3
for (A) and (B) and n= 4 for
(C). Statistical significance
was determined using paired
Student’s t-test. * < 0.05.
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potent functions of VEGF is in antiapoptotic signaling [36].
The antiapoptotic effect of VEGF has previously been dem-
onstrated by Spyridopoulos et al. They demonstrated that re-
combinant VEGF was capable of protecting up to 90% of
epithelial cells from TNF-a-induced apoptosis in vitro.
Therefore, the potential role for MSC-produced VEGF in
protecting B cells from apoptosis was examined.
VEGF production by B cells cultured alone was very low
at 24, 48, and 72h (Fig. 4A–C) while MSC cultured alone
produced 1 ng/mL VEGF at 24, 48, and 72h. However, when
MSC were cultured in the presence of B cells VEGF pro-
duction was significantly increased after 48 and 72h (Fig. 4B,
C). Interestingly, the increase in VEGF production was not
present in samples where B cells were separated from MSC
by transwell membranes (Fig. 4B, C). To further clarify the
source of VEGF production following MSC and B cell co-
cultures in the presence of the activation cocktail, intracel-
lular cytokine staining for VEGF was carried out on the
coculture after 48 h. While only a small proportion of B cells
produced low levels of VEGF, MSC produced significantly
higher levels of VEGF (Fig. 4D) demonstrating that MSC
were the major source of VEGF produced in the coculture.
To determine the significance of the increased VEGF
production on the survival of B cells, a VEGF inhibitor
(SU5416) was added to B cell:MSC cocultures for 72 h
before B cell viability was determined by Annexin V/PI
staining. Inhibition of VEGF signaling during direct B
cell:MSC coculture completely abrogated the promotion of
B cell survival by MSC (Fig. 5A, B). Inhibiting VEGF
signaling resulted in a significant reduction in the percentage
and number of Annexin V and PI-negative B cells after
MSC coculture, restoring them to similar levels as observed
when B cells were cultured alone (Fig. 5A, B). These results
demonstrate that cell contact-dependent upregulation of
VEGF by MSC induced B cell survival.
VEGF production by MSC increases AKT
phosphorylation and prevents caspase 3 activation
Following the demonstration of the importance of MSC-
derived VEGF, this study sought to investigate the signaling
cascade involved in promoting B cell survival. VEGF signaling
has previously been shown to induce cell survival through the
phosphorylation of AKT [37]. Phoshphorylation of AKT
FIG. 4. MSC secrete significantly higher levels of vascular endothelial growth factor (VEGF) following coculture with B
cells. CD19+ peripheral B cells were cultured with or without transwell inserts in the presence or absence of MSC for 72 h.
Supernatant was removed after 24 (A), 48 (B), and 72 (C) h and analyzed for VEGF production by ELISA in triplicate. The
source of the VEGF production following MSC and CD19+ B cell cocultures in the presence of the activation cocktail was
examined by intracellular cytokine staining for VEGF or the appropriate isotype control by flow cytometry. The MSC
population was gated on CD45-CD73+ cells and the B cell population was gated on CD45+CD19+ cells. The bar chart
represents VEGF mean fluorescence intensity (MFI). Statistical significance was determined using either two-way ANOVA
(A–C) or a paired Student’s t-test (D). *< 0.05, ** < 0.005. (A–C) n= 4, (D) n = 3.
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(pAKT) is known to inhibit the activation of the caspase cascade
preventing the expression of cleaved (active) caspase 3 [38].
Therefore, the expression of pAKT and cleaved caspase 3
were analyzed in B cells after 72 h coculture with or without
MSC by western blot. The role of VEGF signaling in pAKT
and cleaved caspase 3 expression was also determined using
VEGF inhibitor. B cells cultured in the presence of MSC
had a marked increase in pAKT expression and displayed
little cleaved caspase 3 (Fig. 5C). B cells that were cultured
alone expressed low levels of pAKT but strong levels of
cleaved caspase 3 (Fig. 5C). The inhibition of VEGF sig-
naling during cocultures with MSC clearly reduced the level
of pAKT expression and restored levels of cleaved caspase 3
to that of B cells cultured alone (Fig. 5C). These data sug-
gest that the increased VEGF production by MSC during
coculture with B cells induces the phosphorylation of AKT
and inhibits the caspase cascade and subsequent cleaved
caspase 3 expression resulting in reduced apoptosis.
MSC enhancement of B cell survival
is not dependent on CXCR4-CXCL12
signaling or EGFR stimulation
As described above, cell contact between MSC and B cells
results in significantly increased VEGF production and inhi-
bition of VEGF signaling prevents MSC support of B cell
survival and restores caspase 3 expression (Fig. 5). To elu-
cidate the cell contact signal responsible for the increased
VEGF production and subsequent support of B cell survival
by MSC, CXCR4-CXCL12 signaling was identified as a
possible candidate. CXCR4 is constitutively expressed on
peripheral B cells [39] and binding of CXCR4 to its ligand
CXCL12 has previously been shown to induce VEGF pro-
duction [40]. The expression of CXCL12 on MSC has pre-
viously been established and therefore, a competitive
inhibitor to CXCR4 (AMD3100) was used to inhibit CXCR4-
CXCL12 signaling during B cell:MSC cocultures. CD19+ B
FIG. 5. VEGF production by MSC is essential for promoting B cell survival. VEGF inhibitor (SU5416) was added to
CD19+ B cell and MSC cocultures for 72 h. B cell survival was determined by analyzing the percentage (A) and total cell
number (B) of Annexin V- PI- B cells after coculture with MSC. Total cell numbers were determined using counting beads.
Viable B cells were distinguished from MSC by gating on CD45+ cells. CD19+ B cells were recovered from coculture and
analyzed for pAKT, AKT, and active Caspase 3 expression by western blot (C). (A–C) Two PBMC donors and two MSC
donors. VEGF inhibitor was reconstituted in DMSO and so DMSO was added to B cell:MSC coculture as a control. (A, B)
Four PBMC donors and two MSC donors. (C) Representative image of two separate experiments using four PBMC donors
and four MSC donors. Statistical significance was determined using a paired Student’s t-test where * < 0.05, **< 0.005.
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cells were isolated from PBMC and cultured in the presence
or absence of MSC (5:1) with or without AMD3100 for 72 h.
B cell viability was determined using Annexin V and PI vi-
ability staining and analyzed by flow cytometry.
Inhibition of CXCR4 did not prevent MSC support of B
cell survival (Fig. 6A) suggesting that the B cell–MSC in-
teraction is not dependent on CXCR4-CXCL12 signaling.
The production of proangiogenic factors by MSC, including
VEGF, is mediated by the EGFR [41]. Stimulation of EGFR
is capable of significantly increasing the production VEGF
by bone marrow-derived human MSC [41]. To investigate
whether B cell–MSC interactions were mediated through
EGFR stimulation, a neutralizing antibody to EGFR was
added to the B cell:MSC (5:1) cocultures. Neutralization of
the EGFR resulted in no detectable differences in B cell
survival after coculture with MSC (Fig. 6B), suggesting that
B cell stimulation of the EGFR is not essential for the in-
crease in VEGF production and the subsequent enhance-
ment of B cell survival by MSC.
Discussion
Bone marrow-derived MSC are currently being investi-
gated as potential new therapies against a wide range of
immune disorders and their ability to suppress T cell [4,5],
DC [6–8], and NK cell function [9,10] has been well
characterized in vitro and in vivo. However, the direct
effect of MSC on B cell biology remains controversial
[18]. Variability among experimental protocols is proposed
as one of the main factors leading to these conflicting
findings [22]. In addition, the mechanism by which MSC
support or suppress B cell biology has not yet been es-
tablished. In this study, we sought to determine how MSC
affect B cell biology in terms of activation, proliferation,
and survival and to elucidate the mechanisms involved in a
well-defined system. MSC support the activation, prolif-
eration, and survival of CD19+ B cells through the cell
contact-dependent upregulation of VEGF and subsequent
inhibition of caspase 3-mediated apoptosis.
Clinical trials have demonstrated the beneficial potential of
MSC as a novel cell therapy, particularly against GvHD,
Crohn’s disease, and myocardial infarction [42–44]. Despite
these recent advances, there are outstanding questions that need
to be addressed before the full potential of MSC therapy can be
realized. The main unresolved issues include the optimal
conditions for large scale manufacturing of MSC, the persis-
tence and biodistribution of MSC in vivo and the widespread
clinical use of MSC therapy without a complete understanding
of their mechanisms of action. B cells are major regulators of
the adaptive immune system and their activation and rapid
proliferation in response to antigen recognition is essential to
the development of a functional immune response [24]. Ac-
cordingly, to develop an effective cell therapy, a complete
understanding of how MSC interact with B cells is essential.
Studies on the effect of MSC on peripheral B cell biology
in vitro have reported conflicting results [13–16,18]. The
majority of the key in vitro published data suggest that MSC
inhibit the proliferation and antibody production of adult B
cells [13,14,17]; contrary to this, however, a number of
published studies suggest that MSC support proliferation
and antibody production [15,16].
More recently, two studies have elegantly demonstrated
that MSC promote the survival of purified B cells, but MSC
inhibition of B cell proliferation and differentiation requires
the presence of purified T cells or whole PBMC [21,22].
Here, we demonstrate that MSC enhanced the activation and
proliferation of purified CD19+ peripheral B cell popula-
tions through a contact-dependent mechanism. This parallels
previous observations [16,21], but importantly identifies that
enhanced B cell activation was not influenced by allogeneic
recognition of MSC.
The clonal expansion of activated B cells is essential for
the development of antibody producing effector B cells and
generally occurs within secondary lymphoid tissues. It is
FIG. 6. CXCR4-CXCL12 contact or epidermal growth factor receptor (EGFR) stimulation is not essential for VEGF-
mediated support of B cell survival by MSC. CD19+ peripheral B cells were isolated from PBMC using positive selection
MACS beads and cultured in the presence or absence of MSC with or without 20 or 50mg/mL CXCR4 inhibitor
(AMD3100) (A). CD19+ B cells were cultured in the presence or absence of MSC with or without 10 nM EGFR inhibitor
(B). B cell viability was determined by analyzing the percentage Annexin V- PI- B cells after coculture with MSC for 72 h.
Viable B cells were distinguished from MSC by gating on CD45+ cells before Annexin V and PI analysis. n = 2 PBMC
donors with 2 MSC donors. Statistical significance was determined using paired Student’s t-test where * < 0.05, **< 0.005.
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now clear that transplanted MSC have the capacity to mi-
grate to lymph nodes [45]. Thus, the administration of MSC
in concurrence with B cell activation may lead to enhanced
expansion of B cells, which in the case of B cell driven or
idiopathic disease may be detrimental to the patient. This
premise is consistent with experimental data; the adminis-
tration of allogeneic MSC in a murine model of lupus re-
sulted in exacerbated disease [46] and is a good example of
the potential adverse effects associated with MSC therapy if
applied without adequate experimental understanding of the
functional mechanisms.
Antibody production by activated B cells is one of the
hallmarks of B cell-mediated disease; however, the ability
of MSC to support or inhibit antibody production is also a
contentious issue. The studies conducted by Traggiai et al.
observed increased IgG and IgM when B cells from lupus
patients were cultured in the presence of MSC, while others
reported increased IgG production by healthy B cells fol-
lowing culture with MSC [15,16,21]. In contrast to these
studies, our data showed that MSC had no effect on the IgG
or IgM production by CD19+ B cells. These differential
findings are probably caused by variances in experimental
setup as the ratio of B cell to MSC, activating molecules and
the purity of B cell populations all differ between studies.
The results presented here were obtained using a B
cell:MSC coculture ratio of 5:1 in an attempt to create a
more physiologically relevant situation than ratios of 1:1 or
1:2 and to determine how MSC directly modulate B cell
biology using B cell instead of whole PBMC. Another
possibility is that the cytokine cocktail used to activate B
cells in this experiment may have been sufficient to maxi-
mize B cell production of IgG and IgM, making it impos-
sible to detect any increases in the presence of MSC. IL-21
is known to induce plasma cell differentiation and IgG
production [47] and is notably absent from the studies that
reported increased IgG [15,16].
In vivo, MSC function as stromal cells and are essential
for maintaining the hematopoietic stem cell niche within the
bone marrow [25,48]. In adults, B cell development occurs
within this MSC supported environment [49] and we hy-
pothesized that in vitro B cell:MSC cocultures mimic the
HSC niche where MSC support the survival of B cells.
Indeed, B cell viability was significantly increased in the
presence of MSC and this was mediated through a cell
contact-dependent mechanism. This result supports previous
work [14,21], but further demonstrates MSC influence on
purified peripheral B cell populations and highlights the
requirement for cell contact.
In contrast to this study, however, Tabera et al. demon-
strated inhibition of B cell proliferation during MSC co-
culture [14]; however, the difference in results between
these two studies likely lies in the activation status of the B
cells. Increased B cell survival when exposed to MSC may
well offer an explanation to the increased activation and
proliferation, as a more viable population of B cells would
be more responsive to the activation cytokines. Thus, the B
cell:MSC interaction is likely to be further modulated by T
cells in vivo; but the major effect of MSC on activated B
cells is supportive of expansion when mature T cells are
absent. This finding has consequences for cell therapy in
terms of disease targets and especially the route and timing
of administration.
While a requirement for cell contact has previously been
identified for MSC support of B cell proliferation [15,16] no
further advances in defining how MSC modulate B cell bi-
ology have been reported. Identifying the mechanisms be-
hind MSC modulation of T cell function has provided a
platform from which to design effective MSC therapies.
Similarly, identifying the mechanism involved in MSC
support of B cell survival would further our understanding
and provide valuable information for future in vivo studies.
With cell contact dependence already established, po-
tential cell surface interacting proteins between MSC and B
cells were investigated. Under normal physiological condi-
tions, BAFF signalling is a potent inducer of B cell ex-
pansion and survival [26]. In addition to this, the expression
of BAFF on the surface of adipocyte-derived MSC has been
described [27]. Although low levels on constitutive BAFF
expression were detected on our bone marrow-derived
MSC, this expression was significantly upregulated follow-
ing stimulation with proinflammatory cytokines IFN-g or
TNF-a suggesting that in the presence of the correct signals
our MSC could express high levels of BAFF. In line with
Franquesa et al. [21], neutralizing BAFF signaling in our
system did not prevent MSC from enhancing B cell prolif-
eration, indicating that MSC support of B cell in vitro ex-
pansion was not dependent on BAFF.
An alternative cell contact-dependent signaling pathway
known to have a role in B cell survival is notch. Notch
signaling is a highly conserved immune regulatory pathway
with established roles in immune cell development, prolif-
eration, differentiation, and survival [29,50]. MSC inhibi-
tion of DC maturation [31] and induction of regulatory T
cells [32] required notch signaling. The role of notch sig-
naling during MSC–immune cell interactions and in B cell
development highlighted notch as a potential contact signal
mediating MSC support of B cell survival. In addition, MSC
have previously been shown to support the survival of B
acute lymphocyte leukemia (B-all) cells via signaling
through notch 3/4 [30]. In this study, however, blocking
studies demonstrated that notch signaling was not essential
for MSC support of B cell survival. The recent study by
Franquesa et al. also ruled out MSC-B cell contact signaling
through IL-6, PGE-2, and a proliferation-inducing ligand
but failed to identify the mechanism of action involved [18].
To elucidate the cell-contact dependent mechanism be-
hind MSC modulation of B cell biology it was necessary to
explore more indirect pathways. MSC are known to mod-
ulate immune cells through the secretion of a wide range of
immunemodulatory soluble factors [1]. Hence, it was hy-
pothesized that cell contact between MSC and B cells was
triggering the production of a soluble antiapoptotic signal
by the MSC, which in turn was promoting B cell survival.
VEGF has been described as one of the most important
factors controlling angiogenesis [51,52] but a role for VEGF
in antiapoptotic signaling has also been established [37]. In
fact, the addition of recombinant VEGF to TNF-a-induced
apoptotic epithelial cells in vitro was sufficient to induce
survival in 80%–90% of cells [53]. VEGF production by
MSC has also been identified as a major contributor to MSC
support of angiogenesis [35]. Therefore, it was hypothesized
that B cell contact stimulated VEGF production by the MSC
and that increased levels of VEGF induced antiapoptotic
signaling in the B cell in our system.
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Interestingly, a significant upregulation in VEGF was
detected following MSC contact with B cells. MSC support
of B cell survival was completely abrogated when VEGF
signaling was blocked. The antiapoptotic signaling pathway
associated with VEGF signaling is mediated through the
phosphorylation of AKT and results in a reduction in cas-
pase 3 cleavage [37,38]. MSC support of B cell survival
mirrored this increase in phosphorylated AKT (pAKT) and
dramatically reduced cleaved caspase 3 expression; this
expression was completely restored by the addition of the
VEGF inhibitor.
Expression of CXCR4 by B cells and CXCL12 by the
MSC [54] in addition to studies demonstrating that CXCR4-
CXCL12 binding facilitates upregulation of VEGF produc-
tion [40] identified CXCR4-CXCL12 as a potential contact
signal required for MSC production of VEGF. However,
inhibiting CXCR4 binding in our system had no effect on
the ability of MSC to promote B cell survival.
An interesting alternative contact signal involved stimu-
lation of the EGFR, a member of the tyrosine kinase family
of receptors, which play an important role in cell survival
and proliferation [55]. Human MSC expression of the EGFR
has previously been reported and its activation results in
significant upregulation of proangiogenic factors including
VEGF [41]. The addition of the EGFR inhibitor to MSC and
B cell cocultures did not prevent MSC support of B cell
survival, suggesting that the elusive cell contact signal be-
tween MSC and B cells was neither CXCR4 nor EGFR.
Conclusion
In conclusion, our data demonstrate the capacity for
MSC to alter B cell biology and presents a step forward in
understanding the mechanism behind how MSC support
the activation, proliferation, and survival of CD19+ B
cells. Although the critical cell contact signal between
MSC and B cells remains to be elucidated, the data pre-
sented here represent a significant progression in under-
standing the mechanism by which MSC support the
activation, proliferation, and survival of CD19+ peripheral
B cells.
This study reveals that cell contact between B cells and
MSC induces a significant upregulation of VEGF production
by MSC. VEGF induces the upregulation of pAKT and in-
hibits caspase 3-mediated CD19+ B cell apoptosis (Fig. 7). To
further the development of MSC toward clinical application it
is essential to clarify exactly how MSC interact with all cells
of the immune response and design more tailored approaches
to MSC treatment. This study has furthered our understanding
of how MSC interact directly with peripheral B cell popula-
tions in vitro and has provided key information for future
studies into the relationship between MSC and B cells.
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FIG. 7. Model of mechanism of action in MSC promotion
of B cell survival. Graphical depiction of proposed mecha-
nism of action behind MSC support of B cell survival. (1) In
our system, MSC bind to CD19+ peripheral B cells (contact
signal yet to be identified). (2) Cell contact signal induces a
significant upregulation of VEGF production by MSC. (3)
Soluble VEGF is bound by vascular endothelial growth
factor receptor (VEGFR) on CD19+ B cells and induces
phosphorylation of AKT. pAKT inhibits the proapoptotic
caspase cascade significantly inhibiting caspase 3 cleavage
and B cell apoptosis.
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